A detailed history of Victory Capital Management Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Victory Capital Management Inc holds 10,085 shares of SNDX stock, worth $142,904. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,085
Previous 10,340 2.47%
Holding current value
$142,904
Previous $212,000 8.49%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$17.93 - $24.81 $4,572 - $6,326
-255 Reduced 2.47%
10,085 $194,000
Q2 2024

Aug 05, 2024

SELL
$18.82 - $23.79 $4,987 - $6,304
-265 Reduced 2.5%
10,340 $212,000
Q1 2024

May 03, 2024

BUY
$19.71 - $24.57 $209,024 - $260,564
10,605 New
10,605 $252,000
Q1 2023

May 02, 2023

SELL
$20.66 - $28.98 $121,294 - $170,141
-5,871 Reduced 26.8%
16,033 $338,000
Q4 2022

Feb 10, 2023

BUY
$20.64 - $26.24 $85,883 - $109,184
4,161 Added 23.45%
21,904 $557,000
Q4 2022

Feb 09, 2023

SELL
$20.64 - $26.24 $213,025 - $270,823
-10,321 Reduced 36.78%
17,743 $451,000
Q3 2022

Nov 02, 2022

BUY
$18.51 - $24.79 $123,202 - $165,002
6,656 Added 31.09%
28,064 $675,000
Q2 2022

Aug 01, 2022

BUY
$13.64 - $19.48 $21,578 - $30,817
1,582 Added 7.98%
21,408 $412,000
Q1 2022

May 04, 2022

BUY
$14.84 - $22.15 $294,217 - $439,145
19,826 New
19,826 $332,000
Q2 2020

Aug 07, 2020

SELL
$8.94 - $20.98 $38,316 - $89,920
-4,286 Closed
0 $0
Q1 2020

May 04, 2020

BUY
$6.65 - $12.03 $1,323 - $2,393
199 Added 4.87%
4,286 $47,000
Q4 2019

Feb 04, 2020

SELL
$5.43 - $9.22 $1,916 - $3,254
-353 Reduced 7.95%
4,087 $38,000
Q3 2019

Nov 12, 2019

BUY
$7.47 - $10.76 $33,166 - $47,774
4,440 New
4,440 $33,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $802M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.